<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03548766</url>
  </required_header>
  <id_info>
    <org_study_id>MRC-02-18-070</org_study_id>
    <nct_id>NCT03548766</nct_id>
  </id_info>
  <brief_title>Using DNA-Typing and Erythrocyte Microparticle Analysis to Detect Blood Doping</brief_title>
  <acronym>Transfusion</acronym>
  <official_title>Using DNA-Typing and Erythrocyte Microparticle Analysis to Detect Homologous/Autologous Blood Doping- a Transfusion Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamad Medical Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>World Anti-doping Agency</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anti-Doping Lab Qatar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sidra Medical and Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laboratorio Antidoping FMSI</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hamad Medical Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total of 12 subjects will be recruited for participation in this study. 6 subjects will
      receive re-infusion of autologous blood, and 6 subjects (anemic patients) will receive a
      homologous transfusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Homologous blood transfusions (HBT) and autologous blood transfusions (ABT) are abused by
      athletes to illegally increase their hemoglobin mass and subsequently improve oxygen
      transport.

      Anti-Doping labs use flow-cytometry to detect HBT in cheating athletes, but athletes avoid
      being tested positive by matching their blood for minor blood groups before transfusion.
      Recent publications suggest that DNA typing by Capillary Electrophoresis or RT-PCR might be
      an alternative way to detect this kind of doping in athletes. Unfortunately, no data exist on
      the clearance of DNA after transfusion of one bag of blood using this methodology.

      For the detection of doping with ABT, there is no direct method available and only the
      biological passport, a longitudinal collection of hematological parameters can indicate
      doping. Recently RBC Microparticles (RBC-MPs) have been described as a potential biomarker
      for autologous transfusion. However, also for this methodology, no data on the clearance time
      of RBC-MPs are available.

      Thus, in this World Anti-Doping Agency (WADA) approved and sponsored project. The
      investigators plan to perform a clinical trial in which six healthy subjects receive an ABT
      and six healthy subjects or patients a HBT. Blood samples will be collected before and at
      several time-points after transfusion. For the detection of HBT the samples will be analyzed
      by the official method (cytometry), and the two genotyping methods (STR and RT-PCR) to
      compare these different techniques and to see if DNA-typing can replace cytometry.

      For the ABT the collected samples will be analyzed for RBC-MPs on a cytometer dedicated for
      Microparticles.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Donor DNA (# of loci with triplets or quadruplets):</measure>
    <time_frame>12 months</time_frame>
    <description>Clearance Kinetics of donor DNA which is transferred during the transfusion of one bag of homologous blood will be established.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cellular Microparticles (10^3/uL):</measure>
    <time_frame>12 months</time_frame>
    <description>Clearance Kinetics of cellular microparticles which are introduced during an autologous blood transfusion and are originating from red blood cells during blood storage will be established.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Blood Disease</condition>
  <condition>Blood Transfusion, Autologous</condition>
  <condition>Blood Doping</condition>
  <condition>Blood Transfusion, Homologous</condition>
  <arm_group>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six healthy subjects will receive an ABT (Autologous Blood Transfusion)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anemic Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six patients with anemia will receive a HBT (Homologous Blood Transfusion)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Homologous Blood Transfusion</intervention_name>
    <description>Homologous, or allogenic, blood transfusions involves someone collecting and infusing the blood of a compatible donor into him/herself.</description>
    <arm_group_label>Anemic Patients</arm_group_label>
    <other_name>Allogenic Blood Transfusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Blood Transfusion</intervention_name>
    <description>Autologous blood transfusion is the collection and re-infusion of the patient's own blood or blood components.</description>
    <arm_group_label>Healthy Subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  both genders,

          -  age 20-50 years and

          -  preferably physically active but no elite athletes subjected to Anti-Doping testing.

        Exclusion Criteria:

          -  vulnerable subjects

          -  not willing to participate

          -  not signing the ICF

          -  patients with end-organ failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sven Voss</last_name>
    <role>Study Chair</role>
    <affiliation>ADLQ</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed Yassin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hamad Medical Corporation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Donati</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laboratorio Antidoping FMSI, Rome, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Costas Georgakopoulos</last_name>
    <role>Principal Investigator</role>
    <affiliation>ADLQ</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammed Alsayrafi</last_name>
    <role>Principal Investigator</role>
    <affiliation>ADLQ</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Charles Grivel</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidra Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christophe Raynaud</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidra Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sven C Voss</last_name>
    <phone>0097455481955</phone>
    <email>svoss@adlqatar.qa</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Abdulqadir Nashwan</last_name>
    <phone>0097466473549</phone>
    <email>anashwan@hamad.qa</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hamad Medical Corporation</name>
      <address>
        <city>Doha</city>
        <country>Qatar</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Yassin</last_name>
    </contact>
    <investigator>
      <last_name>Sven Voss</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohamed Yassin</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zeyd Merenkov</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Saloua Hmissi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aysha Al-Malki</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohammad Abdulla</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Qatar</country>
  </location_countries>
  <reference>
    <citation>Voss SC, Thevis M, Schinkothe T, Schänzer W. Detection of homologous blood transfusion. Int J Sports Med. 2007 Aug;28(8):633-7. Epub 2007 Jul 5.</citation>
    <PMID>17614019</PMID>
  </reference>
  <reference>
    <citation>Giraud S, Robinson N, Mangin P, Saugy M. Scientific and forensic standards for homologous blood transfusion anti-doping analyses. Forensic Sci Int. 2008 Jul 18;179(1):23-33. doi: 10.1016/j.forsciint.2008.04.007. Epub 2008 Jun 2.</citation>
    <PMID>18514452</PMID>
  </reference>
  <reference>
    <citation>Krotov G, Nikitina M, Rodchenkov G. Possible cause of lack of positive samples on homologous blood transfusion. Drug Test Anal. 2014 Nov-Dec;6(11-12):1160-2. doi: 10.1002/dta.1736. Epub 2014 Oct 20.</citation>
    <PMID>25331764</PMID>
  </reference>
  <reference>
    <citation>Donati F, Stampella A, de la Torre X, Botrè F. Investigation on the application of DNA forensic human identification techniques to detect homologous blood transfusions in doping control. Talanta. 2013 Jun 15;110:28-31. doi: 10.1016/j.talanta.2013.02.042. Epub 2013 Mar 18.</citation>
    <PMID>23618171</PMID>
  </reference>
  <reference>
    <citation>Stampella A, Di Marco S, Pirri D, de la Torre X, Botrè F, Donati F. Application of DNA-based forensic analysis for the detection of homologous transfusion of whole blood and of red blood cell concentrates in doping control. Forensic Sci Int. 2016 Aug;265:204-10. doi: 10.1016/j.forsciint.2016.04.021. Epub 2016 Apr 30.</citation>
    <PMID>27175858</PMID>
  </reference>
  <reference>
    <citation>Manokhina I, Rupert JL. A DNA-based method for detecting homologous blood doping. Anal Bioanal Chem. 2013 Dec;405(30):9693-701. doi: 10.1007/s00216-013-7122-8. Epub 2013 Jul 11.</citation>
    <PMID>23842898</PMID>
  </reference>
  <reference>
    <citation>Alizadeh M, Bernard M, Danic B, Dauriac C, Birebent B, Lapart C, Lamy T, Le Prisé PY, Beauplet A, Bories D, Semana G, Quelvennec E. Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. Blood. 2002 Jun 15;99(12):4618-25.</citation>
    <PMID>12036896</PMID>
  </reference>
  <reference>
    <citation>Ni W, Le Guiner C, Moullier P, Snyder RO. Development and utility of an internal threshold control (ITC) real-time PCR assay for exogenous DNA detection. PLoS One. 2012;7(5):e36461. doi: 10.1371/journal.pone.0036461. Epub 2012 May 3.</citation>
    <PMID>22570718</PMID>
  </reference>
  <reference>
    <citation>Almizraq RJ, Seghatchian J, Acker JP. Extracellular vesicles in transfusion-related immunomodulation and the role of blood component manufacturing. Transfus Apher Sci. 2016 Dec;55(3):281-291. doi: 10.1016/j.transci.2016.10.018. Epub 2016 Oct 28. Review.</citation>
    <PMID>27865649</PMID>
  </reference>
  <reference>
    <citation>Straat M, Böing AN, Tuip-De Boer A, Nieuwland R, Juffermans NP. Extracellular Vesicles from Red Blood Cell Products Induce a Strong Pro-Inflammatory Host Response, Dependent on Both Numbers and Storage Duration. Transfus Med Hemother. 2016 Jul;43(4):302-305. Epub 2015 Dec 16.</citation>
    <PMID>27721707</PMID>
  </reference>
  <reference>
    <citation>van der Pol E, Coumans FA, Grootemaat AE, Gardiner C, Sargent IL, Harrison P, Sturk A, van Leeuwen TG, Nieuwland R. Particle size distribution of exosomes and microvesicles determined by transmission electron microscopy, flow cytometry, nanoparticle tracking analysis, and resistive pulse sensing. J Thromb Haemost. 2014 Jul;12(7):1182-92. doi: 10.1111/jth.12602. Epub 2014 Jun 19.</citation>
    <PMID>24818656</PMID>
  </reference>
  <reference>
    <citation>Nielsen MH, Beck-Nielsen H, Andersen MN, Handberg A. A flow cytometric method for characterization of circulating cell-derived microparticles in plasma. J Extracell Vesicles. 2014 Feb 4;3. doi: 10.3402/jev.v3.20795. eCollection 2014.</citation>
    <PMID>24511371</PMID>
  </reference>
  <reference>
    <citation>Rubin O, Crettaz D, Tissot JD, Lion N. Pre-analytical and methodological challenges in red blood cell microparticle proteomics. Talanta. 2010 Jun 30;82(1):1-8. doi: 10.1016/j.talanta.2010.04.025. Epub 2010 Apr 22. Review.</citation>
    <PMID>20685428</PMID>
  </reference>
  <reference>
    <citation>Rank A, Nieuwland R, Crispin A, Grützner S, Iberer M, Toth B, Pihusch R. Clearance of platelet microparticles in vivo. Platelets. 2011;22(2):111-6. doi: 10.3109/09537104.2010.520373. Epub 2011 Jan 13.</citation>
    <PMID>21231854</PMID>
  </reference>
  <reference>
    <citation>Voss SC, Jaganjac M, Al-Thani AM, Grivel JC, Raynaud CM, Al-Jaber H, Al-Menhali AS, Merenkov ZA, Alsayrafi M, Latiff A, Georgakopoulos C. Analysis of RBC-microparticles in stored whole blood bags - a promising marker to detect blood doping in sports? Drug Test Anal. 2017 Nov;9(11-12):1794-1798. doi: 10.1002/dta.2212. Epub 2017 Jun 20.</citation>
    <PMID>28474406</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>May 6, 2018</study_first_submitted>
  <study_first_submitted_qc>May 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2018</study_first_posted>
  <last_update_submitted>November 18, 2019</last_update_submitted>
  <last_update_submitted_qc>November 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hamad Medical Corporation</investigator_affiliation>
    <investigator_full_name>Dr. Mohamed A Yassin ,MD</investigator_full_name>
    <investigator_title>Hematology Consultant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

